This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

Recurrent miscarriage: diabetes drug could ... An existing drug can be used to improve the womb for pregnancy, ... (08 Jan 2020)
Nerve Stimulation May Benefit Women with ... A treatment involving electrical nerve stimulation helped women ... (08 Jan 2020)
Cancer drugs could potentially treat COPD, ... New research from the University of Sheffield shows a certain ... (08 Jan 2020)
Tea drinkers live longer Drinking tea at least three times a week is linked with a longer ... (08 Jan 2020)

Professor Endorses Recent FDA Statements on Use of Aspirin to Prevent a First Heart Attack

Charles H. Hennekens has published an editorial in the current issue of Nature Reviews/Cardiology titled “Aspirin in Primary Prevention Needs Individual Judgments.”
Hennekens, the first to discover that aspirin prevents a first heart attack and is of lifesaving benefit when given during a heart attack or among long-term survivors, was invited by the editor of the journal to provide perspectives on the recent U.S. Food and Drug Administration (FDA) statements that any decision to use aspirin should be an individual clinical judgment by healthcare providers. The authors provide updates to clinicians and their patients on the optimal use of aspirin for the treatment and prevention of a first heart attack.
“All patients suffering a heart attack or blockage of an artery in the brain should receive 325mg of regular aspirin promptly, and daily aspirin thereafter to reduce their death rate as well as subsequent heart attacks and strokes," said Hennekens. “Among long-term survivors of prior heart attacks, occlusive strokes or blockages in the arteries of the legs, aspirin should be continued long-term unless there is a specific contraindication."
In primary prevention, Hennekens and DeMets strongly endorse the recent FDA statement that any judgments about prescribing long-term aspirin for apparently healthy individuals should be based on individual clinical judgments between the healthcare provider and each of his or her patients. This individual clinical judgment should weigh the absolute risk of a first heart attack against the absolute risk of a major bleed.
“The increasing burden of cardiovascular disease in developed and developing countries underscores the need for more-widespread therapeutic lifestyle changes as well as the adjunctive use of drug therapies of proven net benefit in the primary prevention of cardiovascular disease,” said Hennekens. “These should include statins to lower LDL-cholesterol levels, and various drugs necessary to achieve control of high blood pressure.” Hennekens added that “general guidelines for the utilization of aspirin among all apparently healthy adults are not yet justified.”

Source Newsroom: Florida Atlantic University
Nature Reviews: Cardiology


  • Nescafé 3 in1 LifeCycle HEROES return from South Asia

    Donations for Nescafé 3in1 LifeCycle Challenge 2019 can be sent via sms: 5061 7370 = €2.33; 5061 8920 = €6.99; 5061 9229 = €11.65; or via a call to 5160 2020 = €10, 5170 2005 = €15; and 5180 2006 = €25. Bank details are Swift code VALLMTMT, IBAN number MT 18 VALL 22013000000014814521017, Bank name Bank of Valletta, Account number 14814521017.

  • Give a Gift this Christmas which gives back

    The story of medicine is the story of civilization, from an ancient craft of primitive magic and religion to the sophisticated field of science and technology of today.



Connect with other Medical Professionals on fb in a closed facebook group


We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…